Bioness releases new rehabilitation therapy


Bioness Inc., a Santa Clarita-based provider of rehabilitation therapies, has released the L300 Go System, a new treatment for patients with foot drop and/or muscle weakness related to upper motor neuron disease or injury.

Central nervous system injuries often cause a gait disorder called foot drop. People who have foot drop are unable to raise their foot while walking, and often drag their foot, resulting in instability and increased effort during gait. Many people with such injuries, diseases, and other disabilities also suffer from thigh muscle weakness.

The L300 Go is the first functional electrical stimulation (FES) system to offer comprehensive 3D motion detection of gait events, containing a learning algorithm which analyzes patient movement and offers electrical stimulation precisely when needed during the gait cycle.

“Today’s value-based healthcare model demands that rehabilitative professionals keep patients motivated through superior, more personalized care,” said Todd Cushman, President and CEO of Bioness, in a statement. “With the introduction of the L300 Go, clinicians now have access to technological innovations that keep patients engaged during the recovery process while improving mobility in the clinic and community.”

“The relationships physical therapists develop with their patients play a critical role in meeting recovery goals. The new L300 Go features are faster, more intuitive and allow me to focus on working with the patient during our sessions,” said Kathy SanMartino, physical therapist and outpatient clinical neuro program manager at Casa Colina Hospital and Centers for Healthcare. “Having fewer components to manage – along with the incorporation of multi-channel stimulation – makes set up of the device more convenient for patients. This enables us to maximize therapy sessions and empower patients to work on their recovery goals at home.”

The L300 Go System comes in four configurations to treat multiple forms of foot drop and knee instability. It was cleared by the U.S Food and Drug Administration for commercial use and received CE mark certification in early 2017.

Bioness anticipates fulfillment of home user shipments later this year. Bioness is a provider of implantable and external neuromodulation systems, robotic systems and software based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries.

The privately held company was founded in 2004 with support from entrepreneur and philanthropist Alfred Mann.

Related To This Story

Latest NEWS